

Gut Health in Fibromyalgia and Lupus: Mechanisms and Interventions

1. Gut Health and Disease Mechanisms in Fibromyalgia and Lupus

Gut Microbiome Dysbiosis in Fibromyalgia and Lupus

Both fibromyalgia (FM) and systemic lupus erythematosus (SLE) exhibit disturbances in the gut microbiome ("dysbiosis"), though the specific patterns differ. **Fibromyalgia:** Recent studies have found that women with fibromyalgia have an altered gut microbiota composition compared to healthy controls ¹ ². In particular, FM patients often show reductions in certain short-chain fatty acid (SCFA)-producing bacteria (e.g. *Faecalibacterium* and other Firmicutes) and overrepresentation of other organisms ³ ⁴. In an early landmark study, 100% of fibromyalgia patients tested positive for small intestinal bacterial overgrowth (SIBO) via breath test, versus ~20% of healthy controls ⁵. In fact, SIBO was more prevalent in fibromyalgia than even in irritable bowel syndrome (IBS), and hydrogen gas levels on breath tests correlated with FM pain severity ⁵. This suggests an overabundance of fermenting microbes in the small gut of FM patients, potentially contributing to symptoms. Many fibromyalgia patients also have co-morbid IBS and other functional gut symptoms, hinting at shared etiologies. IBS is diagnosed in a significant subset of FM patients, and both conditions share features like pain hypersensitivity and female predominance ⁶ ⁷. Notably, fibromyalgia patients with IBS have been observed to have greater somatic pain sensitivity than IBS patients without fibromyalgia, pointing to a common underlying mechanism ⁷ ⁸.

Lupus: SLE patients likewise demonstrate a disrupted gut microbiome, but with a profile characteristic of autoimmune disease. Lupus typically features **reduced microbial diversity** (fewer species present) and a shift in dominant bacteria. Patients show a lower Firmicutes/Bacteroidetes ratio (due to reduced Firmicutes like Clostridiales and increased Bacteroidetes) compared to healthy individuals ⁹ ¹⁰. Families that include beneficial fiber-fermenting anaerobes – such as *Ruminococcaceae* and *Lachnospiraceae* – are significantly depleted in lupus, whereas pro-inflammatory taxa like *Enterobacteriaceae* (e.g. *Escherichia coli*) and *Bacteroidaceae* (e.g. *Bacteroides*) are enriched ¹¹ ¹². For example, one study found *Escherichia/Shigella* levels were about 7-fold higher in SLE patients than controls, while *Faecalibacterium* (a butyrate-producer) was nearly 40% lower ¹² ¹³. Such an imbalance – fewer SCFA-producing "good" bugs and more gram-negative "endotoxin"-producing bugs – may favor inflammation. Indeed, *Bacteroidetes* expansion at the expense of *Firmicutes* can lead to less SCFA production (like butyrate), removing a source of immune-regulation and gut barrier support ¹⁴. Mechanistic work indicates this loss of butyrate exacerbates inflammatory responses in lupus ¹⁵. Specific organisms have been implicated in lupus pathogenesis as well. For instance, an overgrowth of *Ruminococcus gnavus* (now reclassified as *Blautia gnavus*) has been strongly linked to active lupus, especially lupus nephritis ¹⁶ ¹⁷. *R. gnavus* blooms coincide with disease flares in some patients ¹⁸. Intriguingly, *R. gnavus* strains isolated from lupus patients have *pathogenic* properties not seen in healthy strains – when colonized into mice, lupus-derived strains induced **marked gut dysbiosis and leaky gut**, as well as higher autoantibody levels ¹⁹ ²⁰. This suggests certain gut microbes in lupus are not just correlated with disease but actively drive autoimmunity.

Intestinal Permeability (“Leaky Gut”) and Immune Activation

A healthy gut lining forms a selective barrier between the microbial world and the host immune system. In both fibromyalgia and lupus, evidence shows this barrier is often compromised, leading to excessive intestinal permeability (the colloquial “leaky gut”). **Fibromyalgia:** Several studies document elevated biomarkers of gut permeability in FM patients. In a 2023 case-control study, fibromyalgia patients had significantly higher blood levels of **zonulin-1** (a protein that modulates tight junctions) and IgG antibodies to dietary proteins, alongside higher levels of **lipopolysaccharide (LPS)** and soluble CD14 – all markers consistent with a leaky gut and bacterial translocation ^{21 22}. In fact, FM patients showed even higher levels of these permeability markers than patients with chronic fatigue syndrome in the same study ²¹. This aligns with an earlier finding that FM patients can have objectively increased gut permeability in both the small intestine and stomach, especially those with co-existing IBS symptoms ²³. A likely consequence of a leaky gut in FM is that bacterial products like LPS enter systemic circulation, triggering immune responses and neuroinflammation. LPS from gram-negative bacteria is a potent endotoxin that can activate macrophages and glial cells via Toll-like receptor 4. **In fibromyalgia, translocated LPS is thought to play a role in pain sensitization:** LPS and the cytokines it provokes have been shown to increase pain sensitivity. Research has demonstrated that elevated circulating LPS in FM could drive microglial activation in the spinal cord and brain, contributing to central sensitization of pain ^{24 25}. Indeed, animal studies indicate that exposing the nervous system to endotoxin amplifies pain pathways. Moreover, in FM patients, the degree of abnormal hydrogen production in SIBO (indicative of microbial overgrowth) correlates with their LPS levels and pain severity ^{24 25}. This suggests a feed-forward loop whereby dysbiosis → leaky gut → LPS & cytokines → nervous system sensitization and widespread pain.

Lupus: SLE patients also frequently exhibit a leaky gut, and it may directly fuel autoimmunity. Increased intestinal permeability in lupus has been correlated with disease activity ²⁶. Patients in active lupus flares show higher plasma levels of zonulin, LPS, and bacterial DNA fragments compared to those in remission ^{19 27}. One study found stool zonulin was significantly elevated in SLE, pointing to impaired tight junction integrity in the gut lining ²⁸. Mechanistic experiments, such as the *R. gnavus* mouse study, provide a causal link: colonization with lupus-associated *R. gnavus* led to **zonulin release** and a spike in gut permeability, which in turn triggered high titers of anti-dsDNA antibodies in the mice ^{19 20}. Notably, treating those mice with a zonulin antagonist (Iarazotide acetate) completely reversed the gut leakiness, suggesting that blocking leaky gut can reduce autoimmune drivers ²⁹. In lupus, a leaky gut allows translocation of microbial components that can mimic self or activate immune cells. For example, *Enterobacteriaceae* overgrowth (like *E. coli*) may release LPS and DNA that stimulate plasmacytoid dendritic cells to produce interferon-α – a key cytokine in lupus pathogenesis. Bacterial products traversing a compromised gut barrier can also deposit in tissues or form complexes that directly provoke autoantibody production. In summary, **intestinal barrier dysfunction is an avenue for systemic inflammation and autoimmunity:** in both FM and SLE, researchers have observed the “gut leak” phenomenon and associate it with symptom severity ^{21 30}.

Gut-Associated Immune Modulation and Systemic Inflammation

Approximately 70% of the body's immune cells reside in the gut and its mucosal lining ³¹. This gut-associated lymphoid tissue constantly samples microbial and dietary antigens, maintaining a delicate balance between tolerance and immunity. Dysbiosis and leaky gut can skew this balance, leading to aberrant immune activation in fibromyalgia and lupus. **Immune Activation in Fibromyalgia:** Historically, fibromyalgia was not considered a classical inflammatory disorder because routine inflammatory markers (CRP, ESR) are

often normal. However, more nuanced immunological studies show evidence of chronic low-grade inflammation and glial (immune cell in CNS) activation in FM ³² ³³. Gut dysbiosis may be a driving factor for this immune tone. The fibromyalgia microbiome (and SIBO in particular) can increase systemic levels of *LPS*, which binds to CD14/TLR4 on innate immune cells, stimulating release of pro-inflammatory cytokines like IL-1 β and TNF α ³⁴. Indeed, FM patients have been found to have elevated circulating IL-1 β correlating with gut permeability markers ³⁵ ³⁶. These cytokines can sensitize peripheral nerves and activate microglia in the spinal cord, amplifying pain transmission (the gut-immune-nervous system axis). Moreover, because roughly 70–80% of immune activity is centered in the gut ³¹, an imbalanced gut microbiota can tilt immune cell populations. For example, certain gut bacteria metabolites promote regulatory T-cells (Tregs) that produce IL-10 (an anti-inflammatory cytokine), whereas others promote inflammatory Th17 or Th1 cells. In fibromyalgia, there is preliminary evidence of reduced Treg function and elevated Th17-related cytokines in some patients, possibly linked to dysbiosis (though fibromyalgia's immune profile is not as well-characterized as lupus).

Immune Dynamics in Lupus: In SLE, the immune system is hyperactive and loses tolerance to self, producing autoantibodies and inflammatory damage in multiple organs. The gut microbiome is increasingly recognized as a key modulator of this autoimmune process ³⁷ ¹⁴. One way is through *molecular mimicry*: microbial peptides can resemble self-antigens and spark cross-reactive antibodies. For instance, *Enterococcus gallinarum* (a pathobiont found translocating from gut to liver in lupus-prone mice) can induce anti-chromatin antibodies that worsen lupus, according to one study ³⁷ ¹⁴. Another well-documented example is *Blautia/R. gnavus* in lupus – it produces a unique polysaccharide that triggers a strong IgG immune response; lupus patients with high anti-*R. gnavus* antibodies tend to have active disease, suggesting a gut-driven autoantibody production loop ³⁸ ³⁹. Beyond specific microbes, **the balance of T helper cell subsets in the gut** appears critical. Lupus patients often have an increased Th17:Treg ratio systemically; gut dysbiosis (with loss of SCFA producers) can contribute to this by depriving the host of SCFAs like butyrate that normally help induce Tregs and suppress Th17 differentiation ¹⁴. Additionally, certain gut bacteria can produce *tryptophan metabolites* that interact with the aryl hydrocarbon receptor (AhR) on immune cells, influencing IL-22 and Th17 responses – disruptions in these pathways have been noted in lupus. For example, low levels of *Lactobacillus* in lupus mice were tied to reduced production of AhR ligands and worse autoimmunity; feeding probiotics restored some immune balance ⁴⁰. In summary, gut dysbiosis in lupus promotes a pro-inflammatory milieu: dendritic cells in the gut may become more activated (e.g. a high-salt diet was shown to activate gut DCs and increase Th17 cells, worsening lupus in an animal model ⁴¹), and aberrant microbial signals (LPS, DNA, flagellin) chronically stimulate innate immunity. The gut mucosal immune system essentially “spills over” – instead of confining immune reactions to the gut, it seeds systemic inflammation and autoimmunity. This helps explain why modulating the gut environment (through diet or probiotics) has been observed to reduce autoantibody levels and inflammatory markers in lupus models ⁴² ⁴³.

Gut-Brain Axis and Neuroimmune Interactions

The gut and brain communicate bidirectionally through neural, endocrine, and immune signaling – often termed the *gut-brain axis*. In conditions like fibromyalgia, which involve pain processing and mood symptoms, the gut-brain axis is especially pertinent. **Fibromyalgia:** The chronic widespread pain in FM is thought to result from central nervous system sensitization and neuroimmune dysregulation. Gut dysbiosis can contribute to this via multiple pathways. One is through vagus nerve signaling: metabolites produced by gut microbes (such as certain fatty acids or neurotransmitter precursors) can stimulate afferent vagal fibers, altering brain function in pain modulation and mood. Another key pathway is immune/inflammatory

signaling – as described, a leaky gut allows LPS and cytokines to activate immune cells *in the nervous system*. Microglia (the brain's resident immune cells) become activated in FM, releasing pro-inflammatory factors that heighten pain sensitivity ⁴⁴. Studies show that **transferring gut microbiota from fibromyalgia patients into healthy mice can induce fibromyalgia-like pain behaviors** ⁴⁵ ². In a 2025 experiment, germ-free mice colonized with FM patient microbiota developed widespread pain hypersensitivity, along with *spinal cord microglial activation and reduced nerve fiber density in skin* ². This striking result demonstrates a causal gut→brain effect on chronic pain. The same study found shifts in metabolites: notably, altered amino acid and bile acid profiles in the FM-colonized mice, implicating those molecules in pain signaling ². Certain microbial metabolites (e.g. *D*-lactate, a product of some gut bacteria) might directly affect nerve function and have been hypothesized to contribute to FM's cognitive symptoms (“fibro fog”) and fatigue. Additionally, gut bacteria produce neurotransmitters or modulators – for instance, some *Lactobacilli* produce GABA, while others influence serotonin production via tryptophan metabolism. Imbalances could therefore affect pain perception and mood. Clinically, many FM patients experience concurrent depression or anxiety, and intriguingly, a recent trial showed probiotics significantly improved not only pain but also depression and anxiety scores in FM ⁴⁶ ⁴⁷. This supports the idea that modulating the gut can favorably influence the brain in fibromyalgia. In short, the gut-brain axis provides a mechanism by which dysbiosis and gut inflammation translate into central sensitization, sustained pain, poor sleep, and mood disturbances characteristic of FM.

Lupus: While SLE is an autoimmune disease, it too has neurological and psychiatric manifestations (termed neuropsychiatric lupus when severe, but even mild cognitive and mood issues are common in SLE). Systemic inflammation originating from the gut can breach the blood-brain barrier, which is itself influenced by gut-derived signals. For example, systemic lupus often features high levels of type I interferons and other cytokines; a leaky gut can exacerbate this cytokinemia, which in turn can impair blood-brain barrier integrity and allow neuroinflammation. There is some evidence that SLE patients have altered gut-brain axis activity – one study noted that lupus patients with active disease had distinct fecal microbial profiles correlating with fatigue and cognitive impairment scores. Though research in lupus's gut-brain connection is nascent, we know SCFAs like butyrate can have neuroprotective, anti-inflammatory effects in the brain (e.g. by promoting microglial M2 polarization). Lack of butyrate in lupus might thus predispose to a more pro-inflammatory brain environment. Additionally, certain gut bacteria can produce metabolites that cross into circulation and affect the brain; one example is *TMAO* (trimethylamine-N-oxide), a metabolite from gut microbial action on choline – elevated *TMAO* has been linked to atherosclerosis in lupus ⁴⁸ and possibly could affect cerebrovascular health. Moreover, mood disorders in lupus (like depression) could conceivably be aided by gut-directed therapies (by analogy to findings in other inflammatory conditions), although concrete trials are lacking. It's noteworthy that interventions like omega-3 fatty acids and vitamin D (often used in lupus to reduce inflammation) also have roles in gut mucosal health and the microbiome, hinting that part of their benefit might come via gut-brain-immune effects.

Summary: The gut-brain axis provides a framework to understand how improving gut health can alleviate not just peripheral inflammation but also central symptoms like pain, fatigue, and mood issues. In fibromyalgia, this connection is well illustrated by gut microbiota transplants causing or relieving pain ⁴⁹ ⁵⁰. In lupus, gut-driven immune signals likely contribute to the overall inflammatory burden that can affect the brain. Thus, nurturing a healthy gut might calm an overactive immune system and, through neuroimmune cross-talk, improve cognitive and psychological well-being in these patients.

Microbial Metabolites and Signaling Pathways

An important aspect of the gut's influence on fibromyalgia and lupus is the plethora of **microbial metabolites** that can modulate host pathways. Key among these are **short-chain fatty acids (SCFAs)** (like acetate, propionate, and butyrate), tryptophan metabolites, bile acids, and others produced by gut microbes. These small molecules can reinforce gut barrier integrity, regulate immune cell function, and even act on distant organs (including joints, muscles, and the brain).

SCFAs: Butyrate and other SCFAs are produced by fermentation of dietary fibers by gut bacteria (especially *Firmicutes* such as *Faecalibacterium* and *Roseburia*). SCFAs serve as fuel for colonocytes and fortify the intestinal barrier by upregulating tight junction proteins. They also have anti-inflammatory effects – for instance, butyrate and propionate engage receptors on immune cells (like GPR43/GPR109A) and generally suppress pro-inflammatory cytokine production while promoting anti-inflammatory IL-10 and regulatory T cells ³⁷ ¹⁴. In lupus, a loss of butyrate-producing microbes has been documented, and this SCFA deficiency is thought to *exacerbate* inflammation ¹⁴. Remarkably, feeding lupus-prone mice a diet high in **resistant starch** (a prebiotic fiber that boosts SCFA production) alleviated lupus-like symptoms: it decreased type I interferon signaling, reduced autoantibody levels, and even lowered mortality in those mice ⁵¹. The mechanism involved resistant starch shifting the microbiota and increasing SCFAs, which in turn reduced the abundance of a potentially harmful microbe (*Lactobacillus reuteri* was mentioned as being reduced) and dampened autoimmune pathways ⁵¹. In fibromyalgia, direct measurements of SCFAs are less reported, but one can infer that FM patients with reduced fiber-fermenters likely have suboptimal butyrate levels. SCFAs may influence fibromyalgia by modulating immune activation and also the nervous system – butyrate, for example, has been shown to increase BDNF (a neurotrophic factor) and modulate pain sensitivity in other contexts. Ensuring a SCFA-rich environment (through diet or probiotics) might thus help reduce the low-grade inflammation seen in FM.

Tryptophan Metabolites: Gut bacteria can catabolize tryptophan (an amino acid) into various metabolites such as indole-derivatives and kynurenine pathway products. Some of these (like indole-3-propionic acid or indole-3-aldehyde) activate the aryl hydrocarbon receptor (AhR) on immune cells and epithelial cells, which can promote mucosal homeostasis and IL-22 production (important for barrier function). In lupus, an imbalance in tryptophan metabolism has been noted; certain beneficial *Lactobacillus* strains help generate AhR ligands from dietary tryptophan that keep Th17 cells in check ¹⁴. A lupus study (Choi et al., 2020) found that supplementing an AhR ligand could reduce disease activity in mice ³⁷, underlining how microbial metabolites interface with immune receptors. In fibromyalgia, altered tryptophan metabolism might relate to serotonin availability and mood/pain – for instance, dysbiosis could potentially shift metabolism toward kynurenine (which can be neurotoxic and contribute to fatigue) rather than serotonin. Although not yet fully elucidated in FM, this is a promising area of the gut–brain link.

Bile Acids: Gut bacteria modify bile acids into secondary bile acids, which can engage farnesoid X receptor (FXR) and TGR5 signaling in the host. Disruptions in the microbiota can lead to bile acid imbalances that affect metabolism and immune cells. In the fibromyalgia FMT mouse study, researchers observed **shifts in bile acid metabolism** accompanying pain behaviors ⁵². Interestingly, when those fibromyalgia-colonized mice were given oral bile acid supplements, their pain responses decreased ⁵². This suggests that lack of certain microbial-derived bile acids might contribute to pain, and reintroducing them is beneficial. In lupus, some studies have found that lupus patients have altered bile acid profiles too, potentially contributing to inflammation (as certain bile acids can be pro-inflammatory if not properly converted by gut microbes). Thus, targeting microbial bile acid metabolism could be another route for therapy.

Other Microbial Signals: Components like peptidoglycans, polysaccharide A (from *Bacteroides fragilis*), or even microbial *capsule* components can influence immune education. *Bacteroides fragilis* PSA, for example, is known to induce regulatory T cells and IL-10; if lupus patients lack such beneficial microbes, they miss out on these tolerogenic signals. Conversely, bacterial products like *Salmonella* curli fibers bound to bacterial DNA can strongly activate immune cells to produce interferon (via TLR and inflammasome pathways) – one study noted such mechanisms may exacerbate lupus ⁵³. And as mentioned earlier, LPS is a major microbial product that ignites TNFα, IL-6, and interferons which are abundantly found in active lupus and likely fibromyalgia (in lower levels). Elevated **TMAO** (from gut microbial metabolism of choline/carnitine) has been identified as a cardiovascular risk factor in lupus, linking gut metabolites to one of lupus’s important comorbidities (heart disease) ⁴⁸.

In summary, *gut microbes act like a biochemical factory*: in health, they produce many compounds that reinforce the gut barrier, promote immune tolerance, and even signal the nervous system. In fibromyalgia and lupus, the dysbiotic microbiome produces a different profile of metabolites – one that may lack sufficient anti-inflammatory and barrier-strengthening molecules (SCFAs, certain indoles, etc.), while possibly generating more pro-inflammatory stimuli (LPS, TMAO, etc.). This metabolic skew is a critical piece of the pathophysiology puzzle and also offers **tangible targets** (like providing prebiotics to boost SCFAs, or using specific probiotics that yield beneficial metabolites).

2. GI-Targeted Interventions for Fibromyalgia and Lupus

Given the substantial influence of gut health on immune and neurological pathways, it is natural to explore therapies that target the gastrointestinal system for managing fibromyalgia and lupus. Below we synthesize dietary interventions, microbiome-modulating therapies, and integrative approaches, emphasizing those with clinical evidence or strong mechanistic rationale. The goal of these interventions is to correct dysbiosis, heal the gut barrier, reduce systemic inflammation, and thereby alleviate disease symptoms.

Dietary Interventions: Anti-Inflammatory and Gut-Friendly Diets

Whole-Foods and Anti-Inflammatory Diets: Both fibromyalgia and lupus patients may benefit from diets that are rich in whole, unprocessed foods and low in pro-inflammatory ingredients. An anti-inflammatory diet typically emphasizes plenty of vegetables, fruits, omega-3 rich foods (fish, flaxseed), nuts, and avoids refined sugars, processed meats, and trans fats. In lupus, no single “lupus diet” is prescribed, but a balanced diet akin to the **Mediterranean diet** (high in fruits, veggies, fish, olive oil) is often recommended to support immune function and reduce cardiovascular risk. Such diets provide fiber (feeding beneficial gut microbes) and antioxidants. There is evidence that ensuring adequate intake of vitamins, minerals, and polyunsaturated fatty acids can *improve immune regulation and reduce SLE disease activity* ⁴¹ ⁵⁴. For example, one review noted that supplementation of vitamins and a moderate protein, plant-forward diet can help lower systemic inflammation in SLE ⁵⁴. In fibromyalgia, emerging research actually puts numbers to the benefits: a 2022 randomized controlled trial tested a diet excluding common pro-inflammatory foods (gluten, dairy, added sugars, ultra-processed foods) combined with a low-FODMAP phase, versus a control diet. After 3 months, the intervention group saw *significant improvements in pain, fatigue, sleep quality, and quality of life* compared to controls ⁵⁵. Fibromyalgia Impact Questionnaire scores dropped and even objective measures like cold pain sensitivity improved, despite no change in CRP ⁵⁵. This suggests diet alone can meaningfully reduce symptom burden in FM.

Elimination Diets (Gluten-Free, etc.): Many patients with fibromyalgia or lupus report food sensitivities – common culprits being gluten, dairy, nightshades, or additives. Non-celiac gluten sensitivity has drawn attention in fibromyalgia. Recent evidence indicates that a **gluten-free diet (GFD)** can help a subset of FM patients, especially those with IBS-like GI symptoms. In a 2023 trial, 20 fibromyalgia patients (none with celiac disease) underwent a 6-month GFD, followed by gluten reintroduction and then a return to GFD (an ABA design). Strikingly, after 6 months gluten-free, patients' Widespread Pain Index scores fell by about 25% (from ~10.3 to 7.7) and Symptom Severity scores by 36% ⁵⁶ ⁵⁷. When gluten was added back, pain and symptom scores spiked again, only to improve upon re-eliminating gluten ⁵⁸. These results, confirmed by the re-challenge, strongly suggest that *gluten was driving symptoms in those patients*, and removing it brought relief ⁵⁹. It's hypothesized that gluten may increase gut permeability via zonulin release in susceptible individuals, or that some FM patients have latent gluten sensitivity that triggers immune activation. Given the overlap of fibromyalgia with IBS (where a subset have non-celiac gluten sensitivity), a trial of GFD may be worthwhile in FM patients with gastrointestinal complaints. In lupus, a gluten-free diet is not standard unless celiac disease is present, but some SLE patients adopt it anecdotally for perceived symptom relief. More universally in lupus, **salt restriction** might be important – a high-salt diet can exacerbate autoimmune responses (promoting inflammatory Th17 cells) ⁴¹, so lupus patients are often counseled to avoid excess sodium (which has the added benefit of blood pressure control).

Low FODMAP and Specific Carbohydrate Approaches: For fibromyalgia patients with bloating, IBS, or SIBO, diets low in fermentable oligo-, di-, monosaccharides and polyols (FODMAPs) can reduce GI symptoms. In the above RCT, the fibromyalgia diet included a low-FODMAP component in the first month ⁶⁰, which likely helped alleviate abdominal pain and normalized bowel habits (indeed, GI symptom scores improved significantly) ⁵⁵. While low-FODMAP is mainly for IBS, it can indirectly improve fibromyalgia by improving sleep and comfort (since IBS flares can amplify FM pain perception). However, low-FODMAP is not typically long-term due to its restrictive nature and potential to reduce microbiome diversity (because it cuts out prebiotic fibers). Some clinicians utilize it transiently, then reintroduce foods gradually. Another approach sometimes mentioned in integrative circles is the Specific Carbohydrate Diet (SCD) or a paleo-style diet to reduce dysbiosis and yeast overgrowth; formal evidence in FM/Lupus is lacking, though.

Dietary Fiber and Prebiotics: A cornerstone of gut health is dietary fiber, as it feeds beneficial microbes that produce SCFAs. Both lupus and fibromyalgia patients should aim for a high-fiber diet (unless contraindicated by GI issues) to foster microbiome diversity and an anti-inflammatory metabolite profile. One caveat: if SIBO is present, too much fiber upfront can worsen bloating/pain; in those cases, treating the SIBO first or using a low-FODMAP variant of a high-fiber diet is prudent. In lupus-prone mice, adding fermentable fiber (resistant starch) was shown to *increase butyrate and mitigate lupus severity*, as noted earlier ⁵¹. We can extrapolate that human lupus patients may also benefit from gradually increasing fiber (vegetables, oats, legumes) to nurture SCFA-producing flora. Notably, a pilot study in SLE found that a diet higher in fiber and lower in sugar correlated with more diverse gut microbiota and lower inflammatory markers (IL-6, CRP), though controlled trials are needed.

Omega-3 and Micronutrients: Although not “gut-specific,” certain dietary supplements frequently used in lupus and fibromyalgia deserve mention. *Omega-3 fatty acids* (fish oil) have known anti-inflammatory effects and can alter gut microbiota composition favorably (e.g., increasing Lactobacilli). Trials in lupus have shown fish oil can reduce disease activity and lower inflammation; part of this effect might be through resolving gut inflammation or enhancing gut barrier function. *Vitamin D* is crucial for mucosal immunity – deficiency is common in lupus and fibromyalgia. Adequate vitamin D supports junctional proteins in the gut and balances immune responses (Vitamin D encourages Tregs). Therefore, maintaining sufficient vitamin D

through diet or supplements may aid gut-immune harmony. Magnesium is another adjunct (important for muscle and nerve function); interestingly, magnesium combined with malic acid (from apples) was reported in early studies to improve fibromyalgia pain/tenderness ⁶¹ ⁶². This leads us to consider fermented apple products and other functional foods in the next sections.

Probiotics, Prebiotics, and Synbiotics

Probiotics: Harnessing beneficial bacteria directly is a logical strategy given the dysbiosis in FM and SLE. Probiotics are live microorganisms (often *Lactobacillus* or *Bifidobacterium* species) that, when ingested in adequate amounts, confer a health benefit to the host. Clinical evidence is growing for their role in these conditions:

- **Fibromyalgia:** A recent double-blind, placebo-controlled trial (published 2024) evaluated a multi-species probiotic in fibromyalgia over 8 weeks. The probiotic (containing ~40 billion CFUs of mixed *Lactobacilli* and *Bifidobacteria*) led to significant improvements in multiple domains: it **reduced pain severity** (VAS pain scores) compared to placebo, and also *improved sleep quality, and reduced depression and anxiety scores* in the fibromyalgia patients ⁴⁶ ⁴⁷. In the same study, a prebiotic (inulin) group saw some benefit (notably improved sleep and a reduction in pain from baseline), but the probiotic's effects were broader and more pronounced ⁴⁶ ⁶³. These results support that altering the gut flora can impact central symptoms like mood and sleep in FM, likely through the gut-brain axis and immune modulation. Separately, a pilot RCT in Spain found that probiotic supplementation improved certain cognitive aspects of fibromyalgia (like attention and impulsivity) ⁶⁴, suggesting neurological benefits. Common strains used in trials include *Lactobacillus acidophilus*, *L. rhamnosus*, *L. casei*, *Bifidobacterium breve*, etc. The exact "best" formulation is not established, but multi-strain products targeting both small and large intestine seem reasonable. Even **yogurt or kefir**, as natural probiotics, have shown anecdotal benefits on IBS symptoms in FM patients.
- **Lupus:** In SLE, much work has been done in animal models – for example, NZB/W lupus mice given *Lactobacillus* probiotics had decreased autoantibody levels and kidney inflammation. Translating to humans, a notable randomized trial in 2022 (Widhani et al.) gave SLE patients a **synbiotic** (a combination of probiotics + prebiotic) for 8 weeks. The synbiotic-treated group showed reduced systemic inflammation: **high-sensitivity CRP levels dropped** significantly and there was a trend towards lower disease activity scores ⁴³ ⁶⁵. Microbiome analysis revealed that probiotics increased the Firmicutes/Bacteroidetes ratio and raised fecal butyrate production in these patients ⁴³. This aligns with the idea that restoring a more "normal" microbiome can tilt the immune system towards a less inflammatory state. Another small trial found that a mixture of five *Lactobacillus* strains (including *L. rhamnosus*, *L. reuteri*, *L. gasseri*, etc.) could **repair the intestinal barrier in lupus mice, lower IL-6 in the gut, and increase IL-10**, fostering an anti-inflammatory environment ⁶⁶. These probiotics also led to expansion of Treg cells and a correction of Th17/Th1 imbalance in lupus models ⁴⁰. While human data is still emerging, a case series reported that SLE patients who took daily probiotics for 3 months had slight improvements in fatigue and a decrease in flare frequency (not definitive, but encouraging). Given that probiotics are generally safe, many rheumatologists are now open to adjunctive probiotic therapy in lupus, especially for patients with active disease or on antibiotics. **Choosing a probiotic:** For lupus, strains of *Lactobacillus* and *Bifidobacterium* are common. Notably, *Lactobacillus fermentum* and *B. bifidum* have been studied for their immune effects

in lupus models ⁶⁷ ⁶⁸ . However, one must consider that lupus patients on immunosuppressants should use high-quality probiotics to avoid infection risk, and always consult their doctor.

Prebiotics: These are nondigestible food components (usually fibers or oligosaccharides) that selectively feed beneficial microbes. Common prebiotics include inulin, fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), and resistant starch. Prebiotics can be obtained through diet (high-fiber foods, green bananas, cooked-and-cooled potatoes for resistant starch) or supplements. In the fibromyalgia trial mentioned, **inulin** at 10g/day was given to one group; it led to improved sleep and some reduction in pain (though not as many parameters as the probiotic) ⁴⁶ ⁶³ . Nonetheless, inulin likely boosted Bifidobacteria in those patients, which might have longer-term benefits. For SLE, prebiotic supplementation has theoretical benefit to raise SCFA levels – resistant starch was efficacious in lupus-prone mice in reducing interferon-driven inflammation ⁵¹ . There is at least one ongoing trial giving resistant starch or inulin to human SLE patients to observe effects on the microbiome and disease markers. Additionally, diets naturally rich in prebiotics (e.g. asparagus, garlic, onions, oats) should be encouraged. Synbiotics (combining pre- and probiotics) seem especially promising: they provide both the beneficial bugs and the fuel to help those bugs colonize. As noted, synbiotics in an RCT improved CRP and microbiome composition in SLE ⁴³ . Fibromyalgia synbiotic trials are not yet common, but logically, a combination (e.g. multi-strain probiotic + a prebiotic fiber supplement) may yield synergistic effects on gut restoration.

Postbiotics: Although not asked explicitly, it's worth noting the concept of postbiotics – these are beneficial microbial metabolites themselves (like butyrate or lactate) given directly. While early in development, one could envision giving butyrate or propionate supplements to lupus patients to calm inflammation. Some functional medicine practitioners already use butyrate capsules (sodium butyrate) for patients with “leaky gut” or autoimmune issues. The evidence is preliminary, but postbiotics might bypass having to alter the microbiome and directly provide the signaling molecules of a healthy microbiome.

In summary, **probiotics and prebiotics have shown considerable promise**. They aim to rebalance the gut ecosystem: increasing microbes that tighten the gut barrier, induce Tregs, produce anti-inflammatory metabolites, and crowd out pathobionts. The choice of probiotic may be tailored – for fibromyalgia, one might emphasize *Bifidobacterium longum* (for its calming effect on the brain via GABA production) and *Lactobacillus plantarum* (known to reduce bloating and LPS). For lupus, perhaps *Lactobacillus casei* (immune-modulating) or *Bifidobacterium bifidum* (shown to help regulate T cells in lupus) ⁶⁹ ⁶⁸ . Combination products or fermented multi-strain probiotics (like **kefir**, which naturally contains on the order of 10–12 strains of bacteria/yeast) might be especially beneficial. Indeed, kefir has demonstrated anti-inflammatory effects in other rheumatic diseases.

Fecal Microbiota Transplantation (FMT)

Fecal microbiota transplant – the transfer of stool from a healthy donor into a patient's gut – is a powerful method to reset the entire gut microbiome. It is an approved therapy for recurrent *C. difficile* infection, and research is expanding into other conditions. **Fibromyalgia:** Exciting new research suggests FMT could be a game-changer for fibromyalgia. In the 2025 McGill-led study, after demonstrating that fibromyalgia microbiota induced pain in mice, the researchers conducted an **open-label trial of oral FMT in 14 women with severe fibromyalgia** ⁷⁰ ⁷¹ . Each patient received 5 doses of encapsulated donor stool (from healthy donors) over a few weeks. The results: **12 of 14 patients (86%)** achieved a clinically significant reduction in pain intensity ⁵⁰ . They also reported improvements in overall symptom burden, better sleep, and reduced anxiety/depression ⁵⁰ . Objective tests showed decreased pain sensitivity to cold. Notably, post-FMT stool

analyses confirmed that the healthy bacteria successfully engrafted in the patients' guts ⁷². Though this was not a placebo-controlled trial (and placebo effects can be substantial in FM), the magnitude of improvement and mechanistic backing (the animal data) make it very compelling. Essentially, replacing the dysbiotic microbiome of FM with a healthy one *reversed* key features of the illness in mice and improved symptoms in humans ² ⁴⁹. This suggests a causal role of the microbiome in fibromyalgia and positions FMT as a potential therapeutic avenue. Of course, more rigorous placebo-controlled trials are needed to confirm efficacy and safety in a larger FM cohort, but these early results are encouraging.

Lupus: In SLE, FMT research is at an earlier stage but growing. Case reports exist of lupus patients who underwent FMT (for concurrent Clostridia infection or other reasons) and unexpectedly had improvements in their lupus markers afterward. A 2022 pilot study in China treated 16 active SLE patients with FMT and observed reduction in disease activity index and partial remission in a few cases (though some patients also had changes in immunosuppressants, so hard to attribute solely to FMT). More systematically, one published study showed that transplanting gut microbiota from lupus-prone mice into healthy mice induced lupus-like immune changes ⁷³. Conversely, FMT from healthy donors into lupus mice alleviated their systemic inflammation. In a small uncontrolled human series, **FMT led to an increase in beneficial SCFA-producing bacteria in SLE patients' guts and a decline in some pro-inflammatory bacteria** ⁷⁴ ⁷⁵. Specifically, post-FMT there was enrichment of Firmicutes genera like *Eubacterium*, *Dorea*, and *Marvinbryantia* (all SCFA producers) and a decrease in *Prevotella*, *Pseudomonas*, and other potentially harmful genera ⁷⁴. Clinically, those SLE patients reported improvements in symptoms like joint pain and fatigue, and some inflammatory markers trended down. While this is early evidence, it highlights the potential of rebalancing the lupus microbiome via fecal transplant. There are safety considerations: lupus patients can be immunosuppressed, so donor screening must be meticulous to avoid introducing any infection. But FMT is generally considered safe when following protocols (e.g., using screened stool capsules or enemas).

At this time, FMT for fibromyalgia or lupus is considered experimental. However, given its success in other conditions and the promising pilot data, it's an area of high interest. In the near future, we might see microbiome-targeted treatments that are *more refined than crude FMT* – for example, defined consortia of beneficial bacteria (sometimes called “Live Biotherapeutic Products”) that could be given instead of whole stool. These could achieve similar effects with less variability. For now, FMT represents proof-of-concept that resetting the gut ecosystem can recalibrate the immune system and neuroinflammatory processes underlying these diseases ⁴⁹ ⁷⁴.

Managing Dysbiosis and Opportunistic Infections (SIBO, “Leaky Gut” Treatments)

Addressing dysbiosis often requires not just adding good bacteria (probiotics/FMT) but also *reducing* or controlling overgrown or pathogenic organisms.

SIBO Treatment: In fibromyalgia, the extremely high prevalence of SIBO noted by Pimentel et al. ⁵ has led some clinicians to routinely test FM patients for SIBO (using lactulose breath tests). If positive, treatment options include non-absorbable antibiotics like **Rifaximin**, or herbal antimicrobials (like oregano oil, berberine, allicin, etc.), which have shown efficacy in SIBO comparable to antibiotics in some studies. Indeed, one study reported that *eradication of SIBO with antibiotics significantly improved fibromyalgia clinical scores* ⁷⁶. Patients who normalized their breath test after rifaximin experienced relief in pain and bloating, whereas those still positive for SIBO had ongoing symptoms ⁷⁷. This suggests treating bacterial overgrowth can directly reduce fibromyalgia severity, likely by lowering the systemic endotoxin load and gut inflammation. Standard rifaximin regimens (e.g. 550 mg TID for 14 days) or a combination of rifaximin +

neomycin (if methane-producing SIBO) might be used. However, relapse can occur, so often a multi-faceted approach including diet (like low-FODMAP or elemental diet for a short period) and prokinetics (to improve gut motility) is adopted to maintain results. Given that FM patients often have slow gut transit or IBS-C, adding a prokinetic (natural options include ginger or 5-HTP; prescription like low-dose naltrexone or prucalopride) can help prevent SIBO recurrence.

Candida and Fungal Dysbiosis: Some integrative medicine doctors postulate that fibromyalgia symptoms in certain patients may be aggravated by yeast overgrowth (candida) in the gut. Chronic antibiotic use or high-sugar diets can predispose to candida dysbiosis. While mainstream research hasn't confirmed "candida causes fibromyalgia," there are case reports where antifungal therapies led to symptom improvement in chronic fatigue and fibromyalgia patients with evidence of candida overgrowth. *Apple cider vinegar (ACV)* is sometimes recommended in this context, as it has mild antifungal properties and can acidify the gut to discourage candida. ACV (especially raw, unfiltered type) contains acetic acid, which in vitro can inhibit *Candida albicans*. Additionally, many patients with FM report sugar cravings or a history of frequent yeast infections; a sugar-free, yeast-free diet plus probiotics (like *Saccharomyces boulardii*, a beneficial yeast that crowds out candida) could help rebalance the gut flora. It must be noted that robust evidence linking candida to fibromyalgia pain is lacking – but practitioners find that if a patient has signs of yeast overgrowth (bloating, sugar cravings, yeast infections, "brain fog"), a trial of an anti-candida regimen (diet low in refined carbs, possibly antifungal herbs or medications, and ACV as a daily tonic) might improve overall well-being. **ACV in gut health** will be discussed more below, but in brief, it may also aid digestion by increasing stomach acidity (low stomach acid can contribute to dysbiosis and poor nutrient absorption).

"Leaky Gut" Repairs: To specifically target intestinal permeability, beyond removing offending microbes, some supplements are used to nourish the gut lining. One popular supplement is **L-glutamine**, an amino acid that serves as fuel for enterocytes. Glutamine has been shown to improve gut barrier function in athletes and in chemotherapy patients; in the context of FM or lupus, there's anecdotal use of high-dose glutamine (5–10 grams daily) to help "seal" a leaky gut. Though direct studies in FM/SLE are lacking, a trial in IBS (some of whom had fibromyalgia) showed glutamine reduced intestinal permeability and symptoms. **Zinc carnosine** is another compound that may strengthen tight junctions and reduce gut inflammation; it's used in ulcer healing and could be considered for those with gut barrier issues. **Colostrum** (rich in IgG antibodies and growth factors) is marketed in some circles for healing the gut lining and binding LPS – again, scientific support in these diseases is preliminary, but mechanistically it's plausible.

Addressing Specific Pathogens: If stool tests or other assessments reveal particular imbalances (say, low *Faecalibacterium prausnitzii* or high *Prevotella copri* or *Klebsiella*), targeted approaches can be taken. For example, *Prevotella copri* overgrowth has been linked to rheumatoid arthritis and possibly lupus; reducing red meat and increasing fiber can reduce *Prevotella* abundance. *Klebsiella* (implicated in arthritis) can be targeted with certain probiotics that produce bacteriocins. These are nuanced interventions tailored to stool analysis results and beyond the scope of broad recommendations, but they illustrate that the future of treating autoimmune and chronic pain conditions may involve personalized microbiome modulation.

Fermented Foods and Apple Cider Vinegar (Integrative Nutritional Approaches)

Fermented Foods: Incorporating fermented foods into the diet is a simple, food-as-medicine approach to improve gut microbiota diversity and immune regulation. Examples of fermented foods are yogurt, kefir (fermented milk), sauerkraut and kimchi (fermented vegetables), kombucha (fermented tea), miso and tempeh (fermented soy), and others. These foods naturally contain live microbes (probiotics) as well as

preformed metabolites (postbiotics) that can benefit the host. A recent human study demonstrated that *eating a high-fermented-food diet can increase microbiome diversity and decrease inflammation*. In a 10-week trial, adults assigned to a fermented foods diet (6 servings/day including yogurt, kefir, kimchi, etc.) showed a **significant rise in gut microbiota diversity and a reduction in multiple inflammatory blood markers (such as IL-6 and IL-1 β)** ⁷⁸ ⁷⁹. This was in contrast to a high-fiber diet which, over the short term, did not lower inflammation in that study. Thus fermented foods seem to uniquely boost beneficial microbes and lower systemic inflammation through mechanisms like increasing IL-10 producing cells and reducing endotoxin signaling. For fibromyalgia and lupus patients, adding 1–2 servings of fermented foods daily could be a gentle way to support gut health. For instance, kefir not only provides Lactobacilli and Bifidobacteria strains but also yeasts and peptides that can modulate immune function. A small pilot in fibromyalgia found that those who ate probiotic-rich yogurt daily reported improvements in digestive symptoms and some reduction in pain flares (possibly due to decreased IBS symptoms). In lupus, fermented foods might help counteract the loss of diversity and Firmicutes; however, one must ensure the foods are not high in salt (kimchi and sauerkraut can be salty, which lupus patients should moderate). Homemade fermented vegetables can be rinsed to reduce sodium, for example.

Apple Cider Vinegar (ACV): ACV is a traditional folk remedy often touted for digestive and anti-inflammatory benefits. It is essentially apple juice fermented first to alcohol (by yeast) and then to vinegar (by *Acetobacter* bacteria), resulting in acetic acid and a variety of enzymes and trace nutrients. How might ACV help fibromyalgia or lupus through gut health? Several potential ways: - *Digestive Aid:* ACV is acidic (pH ~3), and a tablespoon of ACV in water before meals can increase stomach acidity, which may improve protein digestion and nutrient absorption. Better digestion means less undigested food reaching the colon to feed harmful bacteria, potentially reducing dysbiosis and bloating. Some FM patients have low stomach acid or take acid blockers for reflux; ACV could counter hypochlorhydria and thereby indirectly limit bacterial overgrowth in the small intestine. - *Blood Sugar Modulation:* There is evidence that ACV can blunt blood sugar spikes by delaying gastric emptying and improving insulin sensitivity. Stable blood sugar may not directly affect lupus, but in fibromyalgia, avoiding spikes and crashes can help maintain energy levels and reduce perceived pain exacerbations (since crashes can trigger adrenal stress). - *Malic Acid Content:* ACV contains malic acid (from apples) in addition to acetic acid. Interestingly, *malic acid with magnesium* has been studied as a supplement in fibromyalgia: a dose of ~1200 mg malate plus ~300 mg magnesium daily over 6 weeks was reported to reduce pain and tenderness by ~40–50% in some patients ⁶¹ ⁶². Malic acid is involved in the Krebs cycle for energy production; a theory was that it helps alleviate the mitochondrial dysfunction or muscle pain in FM. ACV, being derived from apples, has a smaller amount of malic acid that could contribute to this benefit. Some fibromyalgia sufferers anecdotally report reduced muscle pain and fatigue after taking 1–2 tablespoons of ACV daily, crediting the malic acid. - *Anti-inflammatory and Alkalinizing Claims:* Although vinegar is acidic, paradoxically some naturopaths consider it “alkaline-forming” in the body (meaning it might promote a more alkaline metabolic environment after digestion). The science here is not clear, but a less acidic internal environment is generally thought to be anti-inflammatory. ACV also contains polyphenols like quercetin (from apples) which have antioxidant effects. - *Antimicrobial:* ACV in vitro can kill or inhibit bacteria (including *E. coli*, *Staphylococcus*, *Candida*) at sufficient concentrations. While the dilution one drinks is not strong enough to be a disinfectant, regular ACV consumption might modestly suppress pathogenic bacteria in the upper gut and favor beneficial flora. Some individuals use diluted ACV as a mouthwash to reduce oral bacteria (relevant because oral dysbiosis can seed the gut). In lupus, poor oral health has been linked to disease flares, so maintaining oral and gut microbial balance is important.

Using ACV: A common regimen is 1–2 teaspoons to 1 tablespoon of raw, unfiltered ACV in a glass of warm water, taken before meals or in the morning. It's often mixed with a teaspoon of honey (though lupus

patients with anti-dsDNA might avoid honey due to pollen allergens, and diabetics should watch honey intake). ACV capsules exist but may not have the same efficacy as the liquid. Safety-wise, ACV is generally safe but can cause tooth enamel erosion if not diluted (so one should rinse mouth after, or drink through a straw) ⁸⁰ . Also, if someone has Candida issues, there's a bit of a paradox: some say ACV helps fight candida, others (like the personal account in the *Deming Headlight* article) say ACV can trigger symptoms in those sensitive to yeast products ⁸¹ ⁸⁰ . It likely varies person to person.

For fibromyalgia, ACV is not a cure-all, but it can be part of a holistic regimen. Patients on ACV have reported subtle improvements in energy and reduction in "fibro fog," perhaps due to better gut environment and nutrient absorption ⁸¹ . For lupus, ACV could support digestion and provide some antioxidant benefits, but there is no direct research linking it to disease activity. Given its low risk profile, lupus patients who experience bloating or heartburn might try ACV as a natural remedy (with doctor's okay, especially if they have kidney issues, as vinegar contains potassium).

Other Fermented or Functional Foods: Apart from ACV, other home remedies sometimes used include: - *Kombucha*: a fermented tea rich in organic acids and probiotics. Some fibro/lupus patients enjoy it for gut health, but it does contain a small amount of alcohol and sugar, so moderation is key (4–8 oz a day). - *Fermented turmeric or ginger tonics*: these combine anti-inflammatory spices with fermentation. Turmeric itself (with active ingredient curcumin) is proven to lower inflammatory cytokines and could help joint pain in lupus or muscle pain in fibromyalgia. Fermenting it (e.g., making a ginger-turmeric kvass) might increase bioavailability and add probiotic benefits. - *Bone Broth*: simmered bones release collagen, glutamine, and minerals that are thought to help heal the gut lining. Many integrative protocols for autoimmunity include bone broth. While largely anecdotal, it is nutrient-dense and could complement other gut strategies by providing amino acids like proline and glycine for intestinal repair. - *Dietary polyphenols*: Foods like green tea, cocoa, berries, and spices (e.g., cinnamon) have polyphenols that act as prebiotics and modulate gut microbes. Green tea polyphenols, for instance, can increase *Akkermansia muciniphila* (a beneficial mucosal bacterium) and have been reported to reduce disease activity in lupus mice. So a diet rich in colorful plant foods indirectly supports a healthy microbiome.

Putting It All Together: Comprehensive Gut-Centric Care

To manage fibromyalgia or lupus through the lens of gut health, a comprehensive plan might be constructed, incorporating several of the above interventions:

- **Diet:** Start with an anti-inflammatory, whole-foods diet (e.g. Mediterranean-style or paleo-style), possibly eliminating gluten and excessive dairy for a trial period, and reducing refined sugars. Emphasize fiber, unless severe bloating suggests SIBO (in which case moderate fiber until SIBO is treated). Include fermented foods daily if tolerated.
- **SIBO Testing/Treatment:** If the patient has significant GI symptoms (bloating, gas, diarrhea/constipation), test for SIBO and treat if positive (antibiotics like rifaximin or herbal protocols). This often yields improvements in pain and energy in fibromyalgia, as noted by Pimentel's work ⁷⁶ ⁸² . In lupus, treating SIBO can reduce immune stimulation (though SIBO is less documented in lupus specifically, general gut infections should be cleared).
- **Probiotics/Synbiotics:** Add a daily high-quality probiotic supplement, or at least probiotic-rich foods. For active lupus, a multispecies probiotic (including *L. casei*, *L. acidophilus*, *B. bifidum*, etc.) could help

balance Th17/Treg as shown in studies ⁴⁰. For fibromyalgia, a probiotic that also targets mood (such as one containing *Bifidobacterium longum* 1714 or *L. helveticus* strains, sometimes marketed as “psychobiotics”) might give added benefit for anxiety/depression symptoms alongside pain relief.

- **Prebiotics:** If tolerated, incorporate a prebiotic powder (like partially hydrolyzed guar gum, inulin, or a product containing FOS/GOS). Start low dose to avoid gas, and increase gradually. Alternatively, ensure plenty of prebiotic foods: oats, flaxseed, onions, garlic, bananas. Watch for any symptom exacerbation (if so, back down, as too much fiber in an inflamed gut can sometimes cause discomfort initially).
- **Supplements for Gut Lining:** If testing (like Zonulin or stool studies) suggests leaky gut, consider glutamine 5g twice daily, zinc carnosine 75 mg, and possibly colostrum or a supplement blend designed for gut repair (often containing marshmallow root, slippery elm, etc. – demulcents that soothe the gut wall). While these are more “folk” remedies, a small trial in chronic fatigue (a condition overlapping with fibromyalgia) showed improved gut integrity with such supplements.
- **Apple Cider Vinegar:** Suggest 1 tsp in water before two of the meals each day to aid digestion. Monitor how the patient feels – some might feel heartburn (then they should stop), others might feel a reduction in bloating. As the *Deming Headlight* piece mentions, one individual with CFS/FMS noticed increased energy after a week of taking ACV + magnesium routinely ⁸¹. It’s a low-cost intervention that could benefit some.
- **Lifestyle Factors:** Remember that stress and poor sleep also harm the gut (stress can alter microbiome composition and increase permeability via cortisol). So mind–gut practices like yoga, meditation, or even activation of the vagus nerve (through deep breathing or biofeedback) can indirectly improve gut health. Moderate exercise can promote a more diverse microbiome too. And avoiding NSAIDs when possible is important, since chronic NSAID use can aggravate gut lining damage (an issue for lupus patients who might use NSAIDs for pain).

Finally, **monitor clinical outcomes:** If a patient’s pain and fatigue improve in concert with changes in gut markers (say their stool calprotectin, a marker of gut inflammation, normalizes, or their zonulin drops), that strengthens the gut-mediated effect hypothesis. As always, these interventions should complement, not replace, standard medical therapies (e.g., immunosuppressants in lupus, analgesics in fibromyalgia as needed). But they offer a route to potentially address the root contributing factor – a dysfunctional gut-immune axis. The current scientific understanding, built on both foundational research and cutting-edge findings, clearly paints the gut as a central player in fibromyalgia and lupus. By healing the gut microbiome and mucosal barrier, we tap into the body’s own regulatory systems: quelling overzealous immunity in lupus, and soothing neuroinflammation in fibromyalgia.

Table: Summary of Gut-Targeted Interventions and Evidence in Fibromyalgia and Lupus

Intervention	Fibromyalgia (FM)	Systemic Lupus Erythematosus (SLE)
Diet (Whole-foods, anti-inflammatory)	<p>– <i>Anti-inflammatory diet (no gluten/dairy/refined sugar)</i> for 3 months improved pain, fatigue, sleep in FM ⁵⁵ .
 – Gluten-free diet led to ↓ pain scores (WPI down 24%) in non-celiac FM; symptoms worsened when gluten reintroduced ⁵⁶ ⁵⁸ .
 – Low-FODMAP diet can relieve IBS symptoms in FM, indirectly easing pain.</p>	<p>– <i>Mediterranean-style diets</i> recommended: provide fiber and antioxidants to modulate immunity ⁵⁴ .
 – High salt intake can worsen lupus (promotes Th17); SLE patients are advised to limit sodium ⁴¹ .
 – Adequate omega-3s, vitamins, and phytoestrogens may help reduce disease activity ⁵⁴ . (E.g., fish oil and vitamin D support immune balance).</p>
Probiotics	<p>– 8-week probiotic (multi-strain 40 billion CFU) significantly improved FM pain, sleep quality, depression, and anxiety vs. baseline ⁴⁶ ⁴⁷ . Pain (VAS) also ↓ vs placebo.
 – Probiotic also improved cognitive function in a pilot FM study ⁶⁴ .
 – Common strains: <i>Lactobacillus acidophilus</i>, <i>L. casei</i>, <i>Bifidobacterium</i> blends.</p>	<p>– Probiotics can induce Tregs and reduce autoantibodies in lupus models ⁴⁰ .
 – A 2022 RCT: 2-month synbiotic (Lactobacilli + fiber) in SLE lowered hs-CRP, increased butyrate-producers, and led to modest disease activity improvement ⁴³ ⁶⁵ .
 – <i>Lactobacillus</i> mixtures repaired gut lining (↓ IL-6, ↑ IL-10) in lupus mice ⁶⁶ .
 – Probiotic (<i>L. fermentum</i> and <i>B. breve</i>) prevented hypertension and lowered autoantibodies in a lupus mouse model ⁶⁷ .</p>
Prebiotics	<p>– <i>Inulin</i> (10 g/day) for 8 weeks in FM ↓ pain and improved sleep quality (vs baseline) ⁸³ .
 – Prebiotic fibers (e.g. resistant starch, FOS) feed SCFA-producing gut flora; likely beneficial if tolerated.
 – FM patients often try fiber supplements for constipation and gut health (with gradual increase to avoid bloating).</p>	<p>– <i>Resistant starch</i> increased SCFAs and alleviated lupus-like symptoms in mice (↓ IFN-I pathway, ↓ mortality) ⁵¹ .
 – Prebiotics (FOS/inulin) in SLE models fostered Tregs and balanced Th17/Th1 cells ⁴⁰ .
 – An ongoing trial is examining inulin in human SLE for reducing gut permeability (results pending).
 – Diets naturally high in prebiotics (fruits, legumes) are encouraged in lupus for general health.</p>

Intervention	Fibromyalgia (FM)	Systemic Lupus Erythematosus (SLE)
Fecal Microbiota Transplant (FMT)	<p>– <i>Open-label trial</i>: 14 severe FM patients got oral FMT; 12 of 14 had significant pain reduction and symptom improvement ⁵⁰ .
 – Mice receiving FM-patient microbiota developed FM-like pain and immune changes, which were <i>reversed</i> by FMT from healthy donors ² ⁴⁹ .
 – Indicates microbiome plays causal role in FM pain ² ⁵⁰ . RCTs in progress to confirm efficacy.</p>	<p>– Still experimental. Case reports and pilot data suggest FMT can increase microbial diversity and possibly reduce inflammation in SLE ⁷⁴ .
 – SLE patients after FMT showed ↑ Firmicutes (butyrate-producers) and ↓ pro-inflammatory Proteobacteria ⁷⁴ . Some reported symptom relief, but controlled trials needed.
 – Caution: immunosuppression in SLE means donor screening must be thorough.</p>
Treating Dysbiosis (SIBO, etc.)	<p>– Antibiotics for SIBO: 42/42 FM patients had SIBO in one study; treating SIBO (e.g. rifaximin) led to symptom improvement ⁷⁷ ⁸⁴ . Pain correlates with breath hydrogen levels ⁵ .
 – Herbal antimicrobials: Oregano oil, berberine, etc., can also eradicate SIBO and have been used in FM with success rates comparable to rifaximin (per some GI studies).
 – Antifungals: In FM with candida overgrowth signs, nystatin or herbal antifungals plus low-sugar diet are sometimes employed (anecdotal reports of improved fatigue).
 – Gut lining support: Glutamine, zinc-carnosine, etc., used to help “leaky gut” in FM (evidence extrapolated from IBS studies).</p>	<p>– Antibiotics: Broadly, infections (like H. pylori, UTIs, etc.) should be treated in SLE as they can trigger flares. Gut-targeted antibiotic strategies are not routine, but if SIBO or gut infection is identified, treat it to reduce immune stimulation.
 – “Leaky gut” support: No formal guidelines, but some lupus patients empirically use glutamine or colostrum to improve gut barrier (given lupus patients often have elevated zonulin ³⁸).
 – Disease-modifying gut strategies: Research into spore-based probiotics or even phage therapy to reduce specific lupus-associated bacteria (like <i>R. gnavus</i>) is on the horizon, aiming to selectively correct dysbiosis without broad antibiotics.</p>

Intervention	Fibromyalgia (FM)	Systemic Lupus Erythematosus (SLE)
Fermented Foods & ACV	<p>– Regular fermented food intake (yogurt, kefir, kimchi) can increase microbiome diversity and lower inflammation ⁷⁸ . FM patients with IBS may find kefir or yogurt reduces bloating and improves bowel regularity (small studies show kefir reduced GI symptoms and some pain).
 – ACV (1–2 tbsp/day in water) is a popular FM remedy: it may improve energy and reduce pain sensitivity (possibly via malic acid + magnesium effects) ⁶¹ ⁸¹ . Some FM patients report less morning stiffness and brain-fog with ACV.
 – ACV helps digestion; one trial in indigestion (not FM-specific) found vinegar improved gastric emptying. Improved digestion = less gut-derived discomfort for FM.</p>	<p>– Fermented foods provide <i>safe exposure to microbes</i> and have been suggested in lupus to restore lost microbial diversity (with caution on salt). No direct clinical trial, but mechanistically promising for improving immune tolerance.
 – ACV in lupus: mainly anecdotal. Some SLE patients use ACV to aid digestion (especially if on NSAIDs which can impair stomach acid). ACV's acetic acid could help nutrient absorption. No known harm in moderate use; just avoid if history of acid reflux or tooth sensitivity (rinse mouth).
 – Fermented black tea (kombucha) and fermented soy (natto) contain DNases and anti-inflammatory compounds that <i>might</i> help clear NETs and reduce inflammation in lupus – an interesting, though unproven, integrative hypothesis.</p>

(Sources: as cited inline above. Fermented foods study from Wastyk et al. 2021 ⁷⁸ ; FM probiotic RCT ⁴⁶ ; Lupus synbiotic RCT ⁴³ ; FM FMT study ⁵⁰ ; Lupus FMT data ⁷⁴ ; SIBO-FM link ⁵ ⁷⁷ ; Gluten-free diet in FM ⁵⁶ .)

Conclusion: Modern science corroborates a concept long suggested by integrative medicine – that the gut is intricately connected to seemingly distant disorders like chronic pain syndromes and autoimmunity. Approximately 70% of the immune system resides in the gut ³¹ , and the crosstalk between gut microbes, intestinal barrier integrity, and immune homeostasis has profound effects throughout the body. In **fibromyalgia**, an altered microbiome and leaky gut appear to drive systemic and central sensitization, thus tending to the gut can ease pain and neuroinflammation. In **lupus**, dysbiosis and gut-derived inflammation can tip the immune system toward autoimmunity, and improving gut health can reinstate some immune balance. The mechanistic understanding now includes identified pathways: from LPS-induced cytokines that activate microglia and peripheral nerves, to SCFAs that induce Tregs and fortify the gut lining, to microbial antigens that molecularly mimic self. Interventions targeting these pathways – whether a high-fiber sauerkraut-enriched diet, a targeted probiotic, or cutting-edge FMT – are showing real potential in clinical studies.

While more research (especially large controlled trials) is needed to refine these approaches, the **holistic management of fibromyalgia and lupus now rightly includes the “forgotten organ” – the gut microbiome**. Patients often report that attending to diet and gut care improves their energy and reduces flares, validating the scientific findings. The future may see routine use of microbiome profiling in these conditions, with personalized gut therapies to complement immunosuppressants or analgesics. In the meantime, adopting gut-friendly practices – anti-inflammatory nutrition, judicious use of probiotics, avoiding gut irritants – stands as a prudent, empowering way for patients to support their health. By

healing the gut, we aim to calm the immune storm of lupus and dial down the pain amplification of fibromyalgia, moving closer to comprehensive and definitive relief.

1 2 32 33 44 45 49 50 52 70 71 72 Mice develop fibromyalgia-like pain after receiving gut microbiota from human patients

<https://medicalxpress.com/news/2025-04-mice-fibromyalgia-pain-gut-microbiota.html>

3 4 21 22 23 34 35 36 Increased gut permeability and bacterial translocation are associated with fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome: implications for disease-related biomarker discovery - PMC

<https://pmc.ncbi.nlm.nih.gov/articles/PMC10512706/>

5 A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing - PubMed

<https://pubmed.ncbi.nlm.nih.gov/15020342/>

6 7 8 24 25 76 77 82 84 Fibromyalgia and Gut Health: SIBO and IBS

<https://www.news-medical.net/health/Fibromyalgia-and-Gut-Health-SIBO-and-IBS.aspx>

9 10 11 12 13 Gut microbiota dysbiosis and associated immune response in systemic lupus erythematosus: impact of disease and treatment | Gut Pathogens | Full Text

<https://gutpathogens.biomedcentral.com/articles/10.1186/s13099-025-00683-7>

14 15 37 40 41 42 43 48 51 53 54 65 66 67 68 69 73 74 75 Frontiers | Microbial dysbiosis in systemic lupus erythematosus: a scientometric study

<https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1319654/full>

16 17 18 19 20 27 29 30 38 39 Frontiers | Sex-dependent Lupus Blautia (Ruminococcus) gnavus strain induction of zonulin-mediated intestinal permeability and autoimmunity

<https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.897971/full>

26 Intestinal permeability correlates with disease activity and DNA ...

<https://pubmed.ncbi.nlm.nih.gov/38460891>

28 Fecal immunoglobulin A (IgA) and its subclasses in systemic lupus ...

<https://www.sciencedirect.com/science/article/abs/pii/S1521661622001887>

31 The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies - PMC

<https://pmc.ncbi.nlm.nih.gov/articles/PMC8001875/>

46 47 63 83 Effect of prebiotic and probiotic supplementation on reduced pain in patients with fibromyalgia syndrome: a double-blind, placebo-controlled randomized clinical trial - PubMed

<https://pubmed.ncbi.nlm.nih.gov/37224267/>

55 60 Frontiers | An anti-inflammatory and low fermentable oligo, di, and monosaccharides and polyols diet improved patient reported outcomes in fibromyalgia: A randomized controlled trial

<https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.856216/full>

56 57 58 59 Efficacy of a gluten-free diet in reducing the widespread pain index and symptom severity scale in patients affected by fibromyalgia | Reumatismo

<https://www.reumatismo.org/reuma/article/view/1530>

61 62 80 81 Fibromyalgia, Chronic Fatigue Syndrome, Magnesium

<https://www.demingheadlight.com/2016/11/25/fibromyalgia-chronic-fatigue-syndrome-magnesium/>

64 A Pilot Randomized Controlled Trial to Explore Cognitive ... - PubMed

<https://pubmed.ncbi.nlm.nih.gov/30026567/>

78 79 Gut Microbiota-Targeted Diets Modulate Human Immune Status - PMC

<https://pmc.ncbi.nlm.nih.gov/articles/PMC9020749/>